Literature DB >> 16952108

Allergic contact dermatitis caused by latanoprost ophthalmic solution.

C-H Lai1, I-C Lai, C-C Chi.   

Abstract

PURPOSE: Latanoprost is a prostaglandin F2 alfa analog that lowers intraocular pressure by increasing uveoscleral outflow. Herein we describe two cases of allergic contact dermatitis (ACD) to latanoprost.
METHODS: A 69-year-old man with open-angle glaucoma developed erythematous erosive swelling of bilateral eyelids after 4 months of latanoprost therapy. An 84-year-old man with open-angle glaucoma had pruritic erythematous plaques on the bilateral lower eyelids after latanoprost therapy for 4 months.
RESULTS: In both cases, latanoprost was discontinued and the condition gradually resolved in 1 month. The eyelid lesions recurred in days upon latanoprost rechallenge, but subsided after cessation of rechallenge.
CONCLUSIONS: ACD should be suspected if patients on latanoprost therapy have pruritus, erythema, swelling, or erosions on the eyelids even when the symptoms appear after several months of therapy, especially in the elderly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952108     DOI: 10.1177/112067210601600423

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  3 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

2.  Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects.

Authors:  Shiro Mizoue; Tadashi Nakano; Nobuo Fuse; Aiko Iwase; Shun Matsumoto; Keiji Yoshikawa
Journal:  Clin Ophthalmol       Date:  2014-02-03

3.  Allergic contact dermatitis caused by topical eye drops containing latanoprost.

Authors:  Ji Hye Lee; Tae Hyung Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2014-04-30       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.